adoptive tumor-infiltrating lymphocyte therapy

Adoptive tumor-infiltrating lymphocyte (TIL) therapy is an autologous cell-based immunotherapy being developed by the Leids Universitair Medisch Centrum (LUMC) for the treatment of advanced non-small cell lung cancer (NSCLC). The therapeutic process involves surgically resecting a portion of the patient's tumor to isolate naturally occurring T cells that have already recognized and infiltrated the tumor microenvironment. These lymphocytes are then expanded ex vivo to billions of cells using high-dose interleukin-2 (IL-2). The resulting polyclonal cell product, which contains T cells capable of recognizing a diverse array of patient-specific neoantigens, is re-infused into the patient following a non-myeloablative lymphodepleting chemotherapy regimen. This approach is specifically being investigated for patients who have progressed on standard-of-care immune checkpoint inhibitors, aiming to provide a robust and durable anti-tumor immune response by overcoming local immunosuppression.

Other names

TIL therapyadoptive TIL therapyautologous tumor-infiltrating lymphocytes